3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Classical hematology
2
Gastrointestinal
1
Conditions
Venous Thrombosis
2
Venous Thromboembolism
2
Pulmonary Embolism
2
Gastrointestinal Neoplasms
1
Interventions
apixaban
5
Rivaroxaban
5
Dalteparin
4
Enoxaparin
3
edoxaban
2
abelacimab
2
Tinzaparin
2
MAA868
2
Heparin, Low-Molecular-Weight
2
Dabigatran
2
isoquercitrin
1
calcium heparin
1
betrixaban
1
bemiparin
1
Warfarin
1
Heparin
1
Gemcitabine
1
Fondaparinux
1
AVE 5026
1
ALT-836
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Venous Thromboembolism
×
abelacimab
×
Clear all
NCT05171075
2026-04-17
MAGNOLIA
Anthos Therapeutics, Inc.
Phase 3
Terminated
417 enrolled
NCT05171049
2026-02-23
ASTER
Anthos Therapeutics, Inc.
Phase 3
Terminated
1,150 enrolled